Hypothalamic targets for growth hormone secretagogues
- 1 November 1997
- journal article
- review article
- Published by Wiley in Acta Paediatrica
- Vol. 86 (S423) , 88-91
- https://doi.org/10.1111/j.1651-2227.1997.tb18382.x
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young menJournal of Clinical Endocrinology & Metabolism, 1996
- Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.Proceedings of the National Academy of Sciences, 1995
- Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.Proceedings of the National Academy of Sciences, 1995
- A Nonpeptidyl Growth Hormone SecretagogueScience, 1993
- Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesityJournal of Clinical Endocrinology & Metabolism, 1993
- Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal menJournal of Clinical Endocrinology & Metabolism, 1992
- Growth Hormone (GH)-Releasing Peptide Stimulates GH Release in Normal Men and Acts Synergistically with GH-Releasing Hormone*Journal of Clinical Endocrinology & Metabolism, 1990
- Oral activity of the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in rats, dogs and monkeysLife Sciences, 1990
- On thein Vitroandin VivoActivity of a New Synthetic Hexapeptide that Acts on the Pituitary to Specifically Release Growth Hormone*Endocrinology, 1984
- Structure-Activity Relationships of a Synthetic Pentapeptide that Specifically Releases Growth Hormonein Vitro*Endocrinology, 1980